

## Literature

- s41 Jones SA, Hunter CA. Is IL-6 a key cytokine target for therapy in COVID-19? *Nat Rev Immunol* Published Online First: 2021. doi:10.1038/s41577-021-00553-8
- s42 Rosas IO, Bräu N, Waters M, *et al.* Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N Engl J Med* 2021;**384**:1503–16. doi:10.1056/nejmoa2028700
- s43 Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med* 2021;**384**:1491–502. doi:10.1056/nejmoa2100433
- s44 Katz LM. (A Little) Clarity on Convalescent Plasma for Covid-19. *N Engl J Med* 2021;**384**:666–8. doi:10.1056/nejme2035678
- s45 Libster R, Pérez Marc G, Wappner D, *et al.* Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021;**384**:610–8. doi:10.1056/nejmoa2033700
- s46 <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19>.
- s47 <https://www.ema.europa.eu/en/news/ema-issues-advice-use-regn-cov2-antibody-combination-casirivimab-imdevimab>.
- s48 <https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1>.
- s49 Dexamethasone in Hospitalized Patients with Covid-19 | Enhanced Reader. chrome-extension://mbcgpelmjnpfbdnkbbedlfjmeckpnhha/enhanced-reader.html?openApp&pdf=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Fpdf%2F10.1056%2FNEJMoa2021436%3FarticleTools%3Dtrue (accessed 7 Mar 2021).
- s50 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;**395**:497–506. doi:10.1016/S0140-6736(20)30183-5
- s51 Giacomelli A, Pezzati L, Conti F, *et al.* Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: A cross-sectional study. *Clin Infect Dis* 2020;**71**:889–90. doi:10.1093/cid/ciaa330
- s52 Dahm T, Rudolph H, Schwerk C, *et al.* Neuroinvasion and Inflammation in Viral Central Nervous System Infections. *Mediators Inflamm* 2016;**2016**. doi:10.1155/2016/8562805
- s53 Paterson RW, Brown RL, Benjamin L, *et al.* The emerging spectrum of COVID-19 neurology: Clinical, radiological and laboratory findings. *Brain* 2020;**143**:3104–20. doi:10.1093/brain/awaa240
- s54 Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the Nervous System. *Cell* 2020;**183**:16–27.e1. doi:10.1016/j.cell.2020.08.028
- s55 Matschke J, Lütgehetmann M, Hagel C, *et al.* Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. *Lancet Neurol* 2020;**19**:919–29. doi:10.1016/S1474-4422(20)30308-2

- s56 Egervari K, Thomas C, Lobrinus JA, *et al.* Neuropathology associated with SARS-CoV-2 infection. *Lancet* 2021;**397**:276–7. doi:10.1016/S0140-6736(21)00095-7
- s57 Solomon IH, Normandin E, Bhattacharyya S, *et al.* Neuropathological Features of Covid-19. *N Engl J Med* 2020;**383**:989–92. doi:10.1056/nejmc2019373
- s58 Förster M, Weyers V, Küry P, *et al.* Neurological manifestations of severe acute respiratory syndrome coronavirus 2—a controversy ‘gone viral’. *Brain Commun* 2020;**2**. doi:10.1093/braincomms/fcaa149
- s59 Beaud V, Crottaz-Herbette S, Dunet V, *et al.* Pattern of cognitive deficits in severe COVID-19. *J Neurol Neurosurg Psychiatry* 2021;**92**:567–8. doi:10.1136/jnnp-2020-325173
- s60 Filosto M, Cotti Piccinelli S, Gazzina S, *et al.* Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. *J Neurol Neurosurg Psychiatry* Published Online First: 2020. doi:10.1136/jnnp-2020-324837
- s61 Pilotto A, Benussi A, Libri I, *et al.* COVID-19 impact on consecutive neurological patients admitted to the emergency department. *J Neurol Neurosurg Psychiatry* 2021;**92**:218–20. doi:10.1136/jnnp-2020-323929
- s62 Perry RJ, Smith CJ, Roffe C, *et al.* Characteristics and outcomes of COVID-19-associated stroke: A UK multicentre case-control study. *J Neurol Neurosurg Psychiatry* Published Online First: 2020. doi:10.1136/jnnp-2020-324927
- s63 Chou SHY, Beghi E, Helbok R, *et al.* Global Incidence of Neurological Manifestations among Patients Hospitalized with COVID-19 - A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. *JAMA Netw Open* 2021;**4**:1–14. doi:10.1001/jamanetworkopen.2021.12131
- s64 Modin D, Claggett B, Sindet-Pedersen C, *et al.* Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. *Circulation* 2020;:2080–2. doi:10.1161/CIRCULATIONAHA.120.050809
- s65 von Weyhern CH, Kaufmann I, Neff F, *et al.* Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. *Lancet* 2020;**395**:e109. doi:10.1016/S0140-6736(20)31282-4
- s66 Reichard RR, Kashani KB, Boire NA, *et al.* Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. *Acta Neuropathol* 2020;**140**:1–6. doi:10.1007/s00401-020-02166-2
- s67 Nalbandian A, Sehgal K, Gupta A, *et al.* Post-acute COVID-19 syndrome. *Nat Med* 2021;**27**:601–15. doi:10.1038/s41591-021-01283-z
- s68 Taquet M, Geddes JR, Husain M, *et al.* 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The Lancet Psychiatry* 2021;**8**:416–27. doi:10.1016/S2215-0366(21)00084-5
- s69 Barzegar M, Mirmosayyeb O, Gajarzadeh M, *et al.* COVID-19 Among Patients With Multiple Sclerosis. *Neurol - Neuroimmunol Neuroinflammation* 2021;**8**:e1001. doi:10.1212/nxi.0000000000001001

- s70 Alonso R, Silva B, Garcea O, *et al.* COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. *Mult Scler Relat Disord* 2021;**51**:102886. doi:10.1016/j.msard.2021.102886
- s71 Louapre C, Maillart E, Papeix C, *et al.* Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders. *Eur J Neurol* 2020;**7**:1–6. doi:10.1111/ene.14612
- s72 Sormani MP, De Rossi N, Schiavetti I, *et al.* Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. *Ann Neurol* 2021;**89**:780–9. doi:10.1002/ana.26028
- s73 Louapre C, Collongues N, Stankoff B, *et al.* Clinical Characteristics and Outcomes in Patients with Coronavirus Disease 2019 and Multiple Sclerosis. *JAMA Neurol* 2020;**77**:1079–88. doi:10.1001/jamaneurol.2020.2581
- s74 Simpson-Yap S, de Brouwer E, Kalincik T, *et al.* Associations of DMT therapies with COVID-19 severity in multiple sclerosis. *medRxiv* 2021. doi:10.1101/2021.02.08.21251316
- s75 Salter A, Fox RJ, Newsome SD, *et al.* Outcomes and Risk Factors Associated with SARS-CoV-2 Infection in a North American Registry of Patients with Multiple Sclerosis. *JAMA Neurol* Published Online First: 2021. doi:10.1001/jamaneurol.2021.0688
- s76 Haji Abdolvahab M, Moradi-kalbolandi S, Zarei M, *et al.* Potential role of interferons in treating COVID-19 patients. *Int Immunopharmacol* 2021;**90**. doi:10.1016/j.intimp.2020.107171
- s77 Oksbjerg NR, Nielsen SD, Blinkenberg M, *et al.* Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. *Mult Scler Relat Disord* 2021;**52**:102988. doi:10.1016/j.msard.2021.102988
- s78 Bose G, Galetta K. Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis. *Mult Scler Relat Disord* 2021;**52**. doi:10.1016/j.msard.2021.102922
- s79 Langer-Gould A, Smith JB, Li BH. Multiple sclerosis, rituximab, and COVID-19. *Ann Clin Transl Neurol* 2021;**8**:938–43. doi:10.1002/acn3.51342
- s80 Baker D, Roberts CAK, Pryce G, *et al.* COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. *Clin Exp Immunol* 2020;**202**:149–61. doi:10.1111/cei.13495
- s81 Hughes R, Whitley L, Fitovski K, *et al.* COVID-19 in ocrelizumab-treated people with multiple sclerosis. *Mult Scler Relat Disord* 2021;**49**. doi:10.1016/j.msard.2020.102725
- s82 Reder AT, Centonze D, Naylor ML, *et al.* COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies. *CNS Drugs* 2021;**35**:317–30. doi:10.1007/s40263-021-00804-1
- s83 Berger JR, Brandstadter R, Bar-Or A. COVID-19 and MS disease-modifying therapies. *Neurol Neuroimmunol neuroinflammation* 2020;**7**. doi:10.1212/NXI.0000000000000761

- s84 Zrzavy T, Wimmer I, Rommer PS, *et al.* Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown. *Eur J Neurol* Published Online First: 2020. doi:10.1111/ene.14578
- s85 Maghzi AH, Houtchens MK, Preziosa P, *et al.* COVID-19 in teriflunomide-treated patients with multiple sclerosis. *J Neurol* 2020;**267**:2790–6. doi:10.1007/s00415-020-09944-8
- s86 Borriello G, Ianniello A. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. *Mult Scler Relat Disord* 2020;**41**:102165. doi:10.1016/j.msard.2020.102165
- s87 Laroni A, Schiavetti I, Sormani MP, *et al.* COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. *Mult Scler J* 2020. doi:10.1177/1352458520971817
- s88 Sharifian-Dorche M, Sahraian MA, Fadda G, *et al.* COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. *Mult Scler Relat Disord* 2021. doi:10.1016/j.msard.2021.102800
- s89 <https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/>.
- s90 Bsteh G, Bitschnau C, Hegen H, *et al.* Multiple sclerosis and COVID-19: how many are at risk? *Eur J Neurol* Published Online First: 2020. doi:10.1111/ene.14555
- s91 Allen-Philbey K, Stennett A, Begum T, *et al.* Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. *Mult Scler Relat Disord* 2021;**103028**. doi:10.1016/j.msard.2021.103028
- s92 Barun B, Gabelić T, Adamec I, *et al.* Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. *Mult Scler Relat Disord* 2021;**48**. doi:10.1016/j.msard.2020.102704
- s93 Jack D, Damian D, Nolting A, *et al.* COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update. *Mult Scler Relat Disord* 2021;**51**:102929. doi:10.1016/j.msard.2021.102929
- s94 MS International Federation. Global COVID-19 advice for people with MS. 2020;**1–3**. [www.msif.org/covid19data](http://www.msif.org/covid19data)
- s95 Parrotta E, Kister I, Charvet L, *et al.* COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center. *Neurol Neuroimmunol neuroinflammation* 2020;**7**. doi:10.1212/NXI.0000000000000835
- s96 Nabel GJ. Designing Tomorrow's Vaccines. *N Engl J Med* 2013;**368**:551–60. doi:10.1056/nejmra1204186
- s97 Broadbent AJ, Santos CP, Anafu A, *et al.* Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. *Vaccine* 2016;**34**:563–70. doi:10.1016/j.vaccine.2015.11.054

- s98 Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. *Rev Med Virol* 1999;**9**:237–44. doi:10.1002/(SICI)1099-1654(199910/12)9:4<237::AID-RMV252>3.0.CO;2-G
- s99 Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. *Nat Rev Immunol* 2021;**21**:83–100. doi:10.1038/s41577-020-00479-7
- s100 Lee N-H, Lee J-A, Park S-Y, *et al.* A review of vaccine development and research for industry animals in Korea. *Clin Exp Vaccine Res* 2012;**1**:18. doi:10.7774/cevr.2012.1.1.18
- s101 Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. *Nat Med* 2013;**19**:1597–608. doi:10.1038/nm.3409
- s102 Ura T, Yamashita A, Mizuki N, *et al.* New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. *Vaccine* 2021;**39**:197–201. doi:10.1016/j.vaccine.2020.11.054
- s103 Sharma O, Sultan AA, Ding H, *et al.* A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Front Immunol* 2020;**11**. doi:10.3389/fimmu.2020.585354
- s104 Kim SH, Samal SK. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. *Viruses* 2016;**8**. doi:10.3390/v8070183
- s105 Voysey M, Clemens SAC, Madhi SA, *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;**397**:99–111. doi:10.1016/S0140-6736(20)32661-1
- s106 Logunov DY, Dolzhikova I V., Zubkova O V., *et al.* Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet* 2020;**396**:887–97. doi:10.1016/S0140-6736(20)31866-3
- s107 Maruggi G, Zhang C, Li J, *et al.* mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases *Mol Ther* 2019;**27**:757–72. doi:10.1016/j.ymthe.2019.01.020
- s108 Pardi N, Hogan MJ, Porter FW, *et al.* mRNA vaccines—a new era in vaccinology. *Nat Rev Drug Discov* 2018;**17**:261–79. doi:10.1038/nrd.2017.243
- s109 Dong Y, Dai T, Wei Y, *et al.* A systematic review of SARS-CoV-2 vaccine candidates. *Signal Transduct. Target Ther* 2020;**5**. doi:10.1038/s41392-020-00352-y
- s110 Jain A, Rosso M, Santoro JD. Wilhelm Uhthoff and Uhthoff's phenomenon. *Mult Scler J* 2020;**26**:1790–6. doi:10.1177/1352458519881950
- s111 Bohlke K, Davis RL, Marcy SM, *et al.* Risk of anaphylaxis after vaccination of children and adolescents. *Pediatrics* 2003;**112**:815–20. doi:10.1542/peds.112.4.815
- s112 <https://www.cdc.gov/vaccines/vpd/polio/hcp/vaccine-derived-poliovirus-faq.html>.
- s113 <https://www.ema.europa.eu/en/viral-safety-oral-poliovirus-vaccine-opv>.
- s114 <https://www.cdc.gov/vaccines/vpd/polio/public/index.html>.

- s115 Sturkenboom MCJM. The narcolepsy-pandemic influenza story: Can the truth ever be unraveled? *Vaccine* 2015;**33**:B6–13. doi:10.1016/j.vaccine.2015.03.026
- s116 <https://www.pei.de/EN/home/home-node.html;jsessionid=3FE08D54F2B7370B15D4F813BAC66950.intranet212>.
- s117 <https://www.ema.europa.eu/en/medicines/human/EPAR/pandemrix>.
- s118 <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccinestle>.
- s119 Kyriakidis NC, López-Cortés A, González EV, *et al*. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *npj Vaccines* 2021;**6**:28. doi:10.1038/s41541-021-00292-w
- s120 Shinde V, Bhikha S, Hoosain Z, *et al*. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 2021;**384**:1899–909. doi:10.1056/nejmoa2103055
- s121 <https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu>.
- s122 <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine>.
- s123 Logunov DY, Dolzhikova I V., Shcheblyakov D V., *et al*. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021;**397**:671–81. doi:10.1016/S0140-6736(21)00234-8
- s124 NCT04471519. Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers. <https://clinicaltrials.gov/show/NCT04471519> 2020.
- s125 <https://clinicaltrials.gov/ct2/show/NCT04526990>.
- s126 Yang S, Li Y, Dai L, *et al*. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. *Lancet Infect Dis* 2020. doi:10.1101/2020.12.20.20248602
- s127 <https://clinicaltrials.gov/ct2/show/NCT04527575>.
- s128 Xia S, Zhang Y, Wang Y, *et al*. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* 2021;**21**:39–51. doi:10.1016/S1473-3099(20)30831-8
- s129 Zhang Y, Zeng G, Pan H, *et al*. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021;**21**:181–92. doi:10.1016/S1473-3099(20)30843-4
- s130 <https://clinicaltrials.gov/ct2/show/NCT04510207>.
- s131 <https://www.statista.com/chart/24191/number-of-countries-using-selected-covid-19-vaccines/>.



- s132 <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-update-published>.
- s133 <https://clinicaltrials.gov/ct2/show/NCT04516746?term=NCT04516746&draw=2&rank=1>.
- s134 <https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html#!>
- s135 Folegatti PM, Ewer KJ, Aley PK, *et al*. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* Published Online First: 2020. doi:10.1016/S0140-6736(20)31604-4
- s136 [https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf).
- s137 <https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood>.
- s138 [https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-21-may-2021\\_en.pdf](https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-21-may-2021_en.pdf).
- s139 Greinacher A, Thiele T, Warkentin TE, *et al*. A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia Following Coronavirus-19 Vaccination. *Res Sq* 2021;**preprint**:1–8.
- s140 See I, Su JR, Lale A, *et al*. US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Ad26.COVS Vaccination, March 2 to April 21, 2021. *JAMA - J Am Med Assoc* Published Online First: 2021. doi:10.1001/jama.2021.7517
- s141 Scully M, Singh D, Lown R, *et al*. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejmoa2105385
- s142 Cines DB, Bussel JB. SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejme2106315
- s143 Schultz NH, Sørvoll IH, Michelsen AE, *et al*. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejmoa2104882
- s144 Muir K-L, Kallam A, Koepsell SA, *et al*. Thrombotic Thrombocytopenia after Ad26.COVS Vaccination. *N Engl J Med* 2021;**384**:1964–5. doi:10.1056/nejmc2105869
- s145 Greinacher A, Thiele T, Warkentin TE, *et al*. Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. *N Engl J Med* 2021;**384**:2092–101. doi:10.1056/nejmoa2104840

- s146 Chadox F, Simpson CR, Shi T, *et al.* First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Published Online First: *Nature medicine* 2021. doi:10.1038/s41591-021-01408-4
- s147 Sadoff J, Gray G, Vandebosch A, *et al.* Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejmoa2101544
- s148 <https://www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released>.
- s149 <https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough>.
- s150 Karron RA, Key NS, Sharfstein JM. Assessing a Rare and Serious Adverse Event following Administration of the Ad26.COV2.S Vaccine. *JAMA - J Am Med Assoc* 2021;:E1–3. doi:10.1001/jama.2021.7637
- s151 Mahase E. Covid-19: Unusual blood clots are “very rare side effect” of Janssen vaccine, says EMA. *Bmj* 2021;:n1046. doi:10.1136/bmj.n1046
- s152 Shimabukuro TT, Kim SY, Myers TR, *et al.* Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejmoa2104983
- s153 Lumley SF, O’Donnell D, Stoesser NE, *et al.* Antibodies to SARS-CoV-2 are associated with protection against reinfection. *medRxiv* 2020;:2020.11.18.20234369. doi:10.1101/2020.11.18.20234369
- s154 Deisenhammer F, Borena W, Bauer A, *et al.* 6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort. *Wien Klin Wochenschr* 2021;133:351–8. doi:10.1007/s00508-020-01795-7
- s155 Yao L, Wang G-L, Shen Y, *et al.* Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection. *J Infect Dis* Published Online First: 2021. doi:10.1093/infdis/jiab255
- s156 Gudbjartsson DF, Norddahl GL, Melsted P, *et al.* Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med* 2020;383:1724–34. doi:10.1056/nejmoa2026116
- s157 Qureshi H, Ma Z-M, Huang Y, *et al.* Low-Dose Penile SIVmac251 Exposure of Rhesus Macaques Infected with Adenovirus Type 5 (Ad5) and Then Immunized with a Replication-Defective Ad5-Based SIV gag/pol/nef Vaccine Recapitulates the Results of the Phase IIb Step Trial of a Similar HIV-1 Vaccine. *J Virol* 2012;86:2239–50. doi:10.1128/jvi.06175-11
- s158 Mitani K, Kubo S. Adenovirus As An Integrating Vector. *Curr Gene Ther* 2006;2:135–44. doi:10.2174/1566523024605591
- s159 van Doremalen N, Lambe T, Spencer A, *et al.* ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. *Nature* 2020;586:578–82. doi:10.1038/s41586-020-2608-y



- s160 Dai L, Gao GF. Viral targets for vaccines against COVID-19. *Nat Rev Immunol* 2021;**21**:73–82. doi:10.1038/s41577-020-00480-0
- s161 Harvey WT, Carabelli AM, Jackson B, *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat Rev Microbiol* Published Online First: 2021. doi:10.1038/s41579-021-00573-0
- s162 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html>.
- s163 Altmann DM, Boyton RJ, Beale R. Immunity to SARS-CoV-2 variants of concern. *Science* (80-. ). 2021;**371**:1103–4. doi:10.1126/science.abg7404
- s164 Cherian S, Potdar V, Jadhav S, *et al.* Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. *bioRxiv* 2021;:2021.04.22.440932.<https://doi.org/10.1101/2021.04.22.440932>
- s165 Hacısuleyman E, Hale C, Saito Y, *et al.* Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021;:1–7. doi:10.1056/nejmoa2105000
- s166 Cromer D, Juno JA, Khoury D, *et al.* Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. *Nat Rev Immunol* 2021. doi:10.1038/s41577-021-00550-x
- s167 Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? *Nat Rev Immunol* 2021;**21**:340–1. doi:10.1038/s41577-021-00556-5
- s168 Liu Y, Liu J, Xia H, *et al.* BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. *N Engl J Med* Published Online First: 2021. doi:10.1056/nejmc2106083
- s169 Madhi SA, Baillie V, Cutland CL, *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* 2021;**384**:1885–98. doi:10.1056/nejmoa2102214
- s170 Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. *Arch Neurol* 2011;**68**:1267–71. doi:10.1001/archneurol.2011.131
- s171 Zrzavy T, Kollaritsch H, Rommer PS, *et al.* Vaccination in multiple sclerosis: Friend or foe? *Front Immunol* 2019;**10**. doi:10.3389/fimmu.2019.01883
- s172 Hapfelmeier A, Gasperi C, Donnachie E, *et al.* A large case-control study on vaccination as risk factor for multiple sclerosis. *Neurology* 2019;**93**:e908–16. doi:10.1212/WNL.0000000000008012
- s173 Mailand MT, Frederiksen JL. Vaccines and multiple sclerosis: a systematic review. *J Neurol* 2017;**264**:1035–50. doi:10.1007/s00415-016-8263-4
- s174 Achiron A, Dolev M, Menascu S, *et al.* COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. *Mult Scler J* 2021;**27**:864–70. doi:10.1177/13524585211003476
- s175 Löbermann M, Boršo D, Hilgendorf I, *et al.* Immunization in the adult immunocompromised host. *Autoimmun Rev* 2012;**11**:212–8. doi:10.1016/j.autrev.2011.05.015

- s176 Loebermann M, Winkelmann A, Hartung HP, *et al.* Vaccination against infection in patients with multiple sclerosis. *Nat Rev Neurol* 2012;**8**:143–51. doi:10.1038/nrneurol.2012.8
- s177 Rubin LG, Levin MJ, Ljungman P, *et al.* Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. *Clin Infect Dis* 2014;**58**:309–18. doi:10.1093/cid/cit816
- s178 Farez MF, Correale J, Armstrong MJ, *et al.* Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2019;**93**:584–94. doi:10.1212/WNL.0000000000008157
- s179 Lebrun C, Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. *Mult Scler Relat Disord* 2019;**31**:173–88. doi:10.1016/j.msard.2019.04.004
- s180 <https://www.aan.com/Guidelines/Home/GuidelineDetail/974>.
- s181 <https://www.nationalmssociety.org/Living-Well-With-MS/Diet-Exercise-Healthy-Behaviors/Vaccinations>.
- s182 Kelly H, Sokola B, Abboud H. Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. *J Neuroimmunol* 2021;**356**:577599. doi:10.1016/j.jneuroim.2021.577599
- s183 Rubin LG, Levin MJ, Ljungman P, *et al.* 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* Published Online First: 2014. doi:10.1093/cid/cit684
- s184 Bühler S, Eperon G, Ribi C, *et al.* Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. *Swiss Med Wkly* 2015. doi:10.4414/smw.2015.14159
- s185 National Center for Immunization. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;**60**:1–64.
- s186 Cahill J, Izzo A, Garg N. Immunization in Patients With Multiple Sclerosis. *Neurol Bull* Published Online First: 2010. doi:10.7191/neurol\_bull.2010.1020
- s187 Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. *Neurology* 2005;**65**:1964–6. doi:10.1212/01.wnl.0000188901.12700.e0
- s188 Olberg HK, Eide GE, Cox RJ, *et al.* Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. *Eur J Neurol* 2018;**25**:527–34. doi:10.1111/ene.13537
- s189 Von Hehn C, Howard J, Liu S, *et al.* Immune response to vaccines is maintained in patients treated with dimethyl fumarate. *Neurol Neuroimmunol Neuroinflammation* 2018;**5**. doi:10.1212/NXI.0000000000000409
- s190 <https://products.sanofi.us/aubagio/aubagio.html>.

- s191 Bar-Or A, Freedman MS, Kremenchutzky M, *et al.* Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. *Neurology* 2013;**81**:552–8. doi:10.1212/WNL.0b013e31829e6fbf
- s192 Bar-Or A, Wiendl H, Miller B, *et al.* Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. *Neurol Neuroimmunol NeuroInflammation* 2015;**2**:e70. doi:10.1212/NXI.0000000000000070
- s193 <https://www.novartis.us/sites/www.novartis.us/files/gilenya.pdf>.
- s194 Kappos L, Mehling M, Arroyo R, *et al.* Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. *Neurology* 2015;**84**:872–9. doi:10.1212/WNL.0000000000001302
- s195 Mehling M, Hilbert P, Fritz S, *et al.* Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. *Ann Neurol* 2011;**69**:408–13. doi:10.1002/ana.22352
- s196 Achiron A, Mandel M, Dreyer-Alster S, *et al.* Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. *Ther Adv Neurol Disord* 2021;**14**:1–8. doi:10.1177/17562864211012835
- s197 Vågberg M, Kumlin U, Svenningsson A. Humoral immune response to influenza vaccine in natalizumab-treated MS patients. *Neurol Res* 2012;**34**:730–3. doi:10.1179/1743132812Y.0000000059
- s198 Kaufman M, Pardo G, Rossman H, *et al.* Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. *J Neurol Sci* 2014;**341**:22–7. doi:10.1016/j.jns.2014.03.035
- s199 Bar-Or A, Calkwood JC, Chognot C, *et al.* Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. *Neurology* 2020;**95**:e1999–2008. doi:10.1212/WNL.0000000000010380
- s200 Bingham CO, Looney RJ, Deodhar A, *et al.* Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. *Arthritis Rheum* 2010;**62**:64–74. doi:10.1002/art.25034
- s201 <https://products.sanofi.us/lemtrada/lemtrada.html>.
- s202 McCarthy CL, Tuohy O, Compston DAS, *et al.* Immune competence after alemtuzumab treatment of multiple sclerosis. *Neurology* 2013;**81**:872–6. doi:10.1212/WNL.0b013e3182a35215
- s203 <https://www.emdgroup.com/en/news/actrimis-2021-mavenclad-25-02-2021.html>.
- s204 [https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-iii\\_en.pdf](https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-iii_en.pdf).
- s205 <https://www.mssociety.org.uk/what-we-do/news/ms-society-medical-advisers-release-consensus-statement-covid-19-vaccines>.
- s206 <https://www.msif.org/>.

- s207 <https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-with-COVID-19-mRNA-Vaccines>.
- s208 [https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf). [https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf)
- s209 Ufer M, Shakeri-Nejad K, Gardin A, *et al*. Impact of siponimod on vaccination response in a randomized, placebo-controlled study. *Neurol Neuroimmunol NeuroInflammation* 2017;**4**. doi:10.1212/NXI.0000000000000398
- s210 Chun J, Giovannoni G, Hunter SF. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. *Drugs* 2021;**81**:207–31. doi:10.1007/s40265-020-01431-8
- s211 Chilimuri S, Mantri N, Gongati S, *et al*. Covid-19 vaccine failure in a patient with multiple sclerosis on ocrelizumab. *Vaccines* 2021;**9**:1–3. doi:10.3390/vaccines9030219
- s212 Khayat-Khoei M, Conway S, Rubinson DA, *et al*. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. *J Neurol* 2021. doi:10.1007/s00415-021-10463-3
- s213 Braun-Moscovici<sup>1</sup> Y, Kaplan<sup>2</sup> M, Markovits<sup>1</sup> D, *et al*. Humoral response to Pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity. *medRxiv* 2021;:2021.04.02.21254493. <https://doi.org/10.1101/2021.04.02.21254493>
- s214 Deepak P, Kim W, Paley MA, *et al*. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. *medRxiv Prepr Serv Heal Sci* Published Online First: 2021. doi:10.1101/2021.04.05.21254656
- s215 Van Kempen ZLE, Strijbis EMM, Al MMCT, *et al*. SARS-CoV-2 Antibodies in Adult Patients with Multiple Sclerosis in the Amsterdam MS Cohort. *JAMA Neurol* 2021;**106**:4–6. doi:10.1001/jamaneurol.2021.1364
- s216 Sahin U, Muik A, Derhovanessian E, *et al*. Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (Nature, (2020), 586, 7830, (594-599), 10.1038/s41586-020-2814-7). *Nature* 2021;**590**:E17. doi:10.1038/s41586-020-03102-w
- s217 Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. *Nat Rev Immunol* 2021. doi:10.1038/s41577-021-00526-x
- s218 Wienands J. IgG antibody titers to SARS-CoV-2 reveal a distinct efficacy of multiple sclerosis-modifying therapies to curtail lymphocyte compartments. *Ther Adv Neurol Disord* 2021;**14**:175628642110221. doi:10.1177/17562864211022109
- s219 Olberg HK, Cox RJ, Nostbakken JK, *et al*. Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: An explorative study. *Mult Scler J* 2014;**20**:1074–80. doi:10.1177/1352458513513970

- s220 Dagan N, Barda N, Kepten E, *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* 2021;**384**:1412–23. doi:10.1056/nejmoa2101765
- s221 <https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu>.
- s222 <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use>.
- s223 Frenck RW, Klein NP, Kitchin N, *et al.* Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *N Engl J Med* 2021;:1–12. doi:10.1056/NEJMoa2107456
- s224 [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE\\_recommendation-AZD1222-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1).
- s225 Cunningham AL, Lal H, Kovac M, *et al.* Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. *N Engl J Med* 2016;**375**:1019–32. doi:10.1056/nejmoa1603800
- s226 <https://www.astrazeneca.com/media-centre/articles/2021/first-real-world-study-of-covid-19-vaccine-astrazeneca-demonstrates-94-reduction-in-hospitalisations.html>.
- s227 Vasileiou E, Simpson CR, Shi T, *et al.* Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. *Lancet* 2021;**397**:1646–57. doi:10.1016/S0140-6736(21)00677-2
- s228 Hall VJ, Foulkes S, Saei A, *et al.* Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). *SSRN Electron J Published Online First*: 2021. doi:10.2139/ssrn.3790399
- s229 Babazadeh A, Mohseni Afshar Z, Javanian M, *et al.* Influenza vaccination and Guillain–Barré syndrome: Reality or fear. *J Transl Intern Med* 2019;**7**:137–42. doi:10.2478/jtim-2019-0028
- s230 Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management. *J Pediatr* 2010;**156**:623–8. doi:10.1016/j.jpeds.2009.10.015
- s231 Vellozzi C, Burwen DR, Dobardzic A, *et al.* Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring. *Vaccine* 2009;**27**:2114–20. doi:10.1016/j.vaccine.2009.01.125
- s232 Souayah N, Nasar A, Suri MFK, *et al.* Guillain-Barre syndrome after vaccination in United States. A report from the CDC/FDA Vaccine Adverse Event Reporting System. *Vaccine* 2007;**25**:5253–5. doi:10.1016/j.vaccine.2007.03.053
- s233 Zhang C, Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. *Hum Vaccines Immunother* 2016;**12**:2064–74. doi:10.1080/21645515.2016.1165908

- s234 Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. *N Engl J Med* 2021;**384**:643–9. doi:10.1056/nejmra2035343
- s235 Cauchi M, Robertson NP. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2. *J Neurol* 2021;**268**:2002–4. doi:10.1007/s00415-021-10513-w
- s236 Pormohammad A, Zarei M, Ghorbani S, *et al.* Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Vaccines* 2021;**9**:467. doi:10.3390/vaccines9050467
- s237 Kramer DB, Opel DJ, Parasidis E, *et al.* Choices in a Crisis — Individual Preferences among SARS-CoV-2 Vaccines. *N Engl J Med* 2021;**384**:e62. doi:10.1056/nejmp2102146
- s238 Centonze D, Rocca MA, Gasperini C, *et al.* Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. *J Neurol* Published Online First: 2021. doi:10.1007/s00415-021-10545-2
- s239 Nguyen J, Hardigan P, Kesselman MM, *et al.* Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. *Mult Scler Relat Disord* 2021;**48**. doi:10.1016/j.msard.2020.102698
- s240 Jeyanathan M, Afkhami S, Smaill F, *et al.* Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol* 2020;**20**:615–32. doi:10.1038/s41577-020-00434-6
- s241 Moore JP. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy. *JAMA - J Am Med Assoc* 2021;**325**:1251–2. doi:10.1001/jama.2021.3465
- s242 <https://www.health.gov.au/news/health-alerts/novel-coronavirus-2019-ncov-health-alert/coronavirus-covid-19-current-situation-and-case-numbers>.